A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer DiseaseBLACK, Ronald S; SPERLING, Reisa A; SAFIRSTEIN, Beth et al.Alzheimer disease and associated disorders. 2010, Vol 24, Num 2, pp 198-203, issn 0893-0341, 6 p.Article

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer DiseaseBLENNOW, Kaj; ZETTERBERG, Henrik; RINNE, Juha O et al.Archives of neurology (Chicago). 2012, Vol 69, Num 8, pp 1002-1010, issn 0003-9942, 9 p.Article

Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic miceBARD, Frederique; FOX, Michael; FRIEDRICH, Stuart et al.Experimental neurology (Print). 2012, Vol 238, Num 1, pp 38-43, issn 0014-4886, 6 p.Article

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's DiseaseSALLOWAY, Stephen; SPERLING, Reisa; REICHERT, Marcel et al.The New England journal of medicine. 2014, Vol 370, Num 4, pp 322-333, issn 0028-4793, 12 p.Article

Preventing Alzheimer's Disease : Disease PreventionSELKOE, Dennis J.Science (Washington, D.C.). 2012, Vol 337, Num 6101, pp 1488-1492, issn 0036-8075, 5 p.Article